HP 3150

Drug Profile

HP 3150

Alternative Names: HSP3150

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cancer pain
  • Phase II Back pain

Most Recent Events

  • 30 Nov 2016 Hisamitsu Pharmaceutical completes a phase III trial for Cancer pain in Japan (JapicCTI152958)
  • 30 Nov 2016 Hisamitsu Pharmaceutical completes a phase II/III study for Cancer pain in Japan (JapicCTI-152957)
  • 30 Nov 2016 Hisamitsu Pharmaceuticals completes a phase II trial in Back pain in Japan (JapicCTI-153012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top